Press Releases

NEW YORK & TUCKER, Ga.--(BUSINESS WIRE)-- TripleCare, a national provider of telemedicine-based healthcare services to skilled nursing facilities (SNFs), announced today it has in

RA’ANANA, Israel & NEW YORK--(BUSINESS WIRE)-- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation status to the Company’s lead product candidate, UGN-101, (mitomy

WILSONVILLE, Ore.--(BUSINESS WIRE)-- FLIR Systems, Inc. (NASDAQ: FLIR) today announced financial results for the third quarter ended September 30, 2018. “Overall, I was pleased with the third quarter performance,” said Jim Cannon, FLIR President and Chief Executive Officer. “We delivered strong performance reaching our highest quarterly gross margin, operating margin, and operating cash flow i

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced that the Company will present data from the dose escalation portion of its Phase 1 trial of SY-1365, its first-in-class selective cyclin-dependent kinase 7 (CDK7) inhibitor, in advanced solid tumor patients in an oral plenary session at the 30

WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte Corporation (Nasdaq:INCY) today reports 2018 third quarter and nine month financial results and provides a status update on the Company’s development portfolio. “The total number of patients taking Jakafi continues to increase in both approved indications, and we have raised the lower end of our full year revenue guidance,” stated Herv&eacu

FT. WORTH & DALLAS, Texas--(BUSINESS WIRE)-- NanOlogy, a clinical-stage oncology development company, announced today that positive findings from a pharmacokinetic (PK) preclinical s

MILWAUKEE--(BUSINESS WIRE)-- Jason Industries, Inc. (NASDAQ:JASN) (NASDAQ:JASNW) (“Jason” or the “Company”) today reported results for third quarter 2018. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181030005302/en/ Key

LUXEMBOURG--(BUSINESS WIRE)-- Intelsat S.A. (NYSE: I), operator of the world’s first Globalized Network and leader in integrated satellite communications, today announced financial results for the three months ended September 30, 2018. Intelsat reported total revenue of $536.9 million and net loss attributable to Intelsat S.A. of $374.6 million for the three months ended September 30, 20

BOSTON & SAN FRANCISCO--(BUSINESS WIRE)-- Calera Capital, a leading middle-market private equity firm, announced today that it has acquired a majority stake in ImageFIRST, a leading provider of laundry services for the healthcare industry. Jeff Berstein, ImageFIRST’s CEO, the Berstein family and management will retain a significant equity interest in the business. Terms of the transaction were not dis

VANCOUVER, British Columbia--(BUSINESS WIRE)-- Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, announced today that its abstract describing new data from the Company’s adaptive Phase 1 clinical trial for ZW25 has been selected for a plenary session presentation at the 30th EORTC-NCI-AACR Symposium on Molecular Targets and Canc

SANTA BARBARA, Calif.--(BUSINESS WIRE)-- Innovative Micro Technology, Inc. (IMT) announced today a majority equity financing led by Cerium Technology, an i

WALTHAM, Mass.--(BUSINESS WIRE)-- Hypoglycemia in the hospital is common, costly, extremely serious and largely preventable, but many c-suite and business office executives are unaware of what it is, why it occurs or the significant impact it has on patient safety, outcomes and economics. A new eBook from Glytec, offered free of charge at the company's website, shines a light on critical concerns surrounding hy

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)-- Eagle Pharmaceuticals, Inc. (Nasdaq:EGRX) (“Eagle” or the “Company”) today provided preliminary financial results and announced that its Board of Directors has approved a new stock repurchase program providing for the repurchase of up to an aggregate of $150 million of Eagle’s common stock, consisting of (i) up to $50 million in repurchases p

WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced that its team of neuroscience drug discovery experts will present 26 scientific posters, both independently and collaboratively with clients, at Neuroscience 2018, the 48th annual meeting of the Society for Neuroscience (SfN). The meeting, which brings together more than 30,000 re

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)-- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the Company’s fulvestrant formulation has not met the primary bioequivalence endpoints evaluating Eagle’s formulation compared to FASLODEX® in its open label, randomized, pharmacokinetic (PK) and safety study conducted in 600 healthy femal